Grünenthal Report 2023-2024

This is the Grünenthal Report 2023 -2024

4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.

Our most recent report shares information about our company’s strategy, highlight projects and financial performance

2023 also saw solid progress for other key pipeline projects that have the potential to replace opioid therapies, including our Phase III trial to achieve a US label extension for Qutenza to treat post-surgical neuropathic pain (PSNP). With our Glucocorticoid Receptor Modulator (GRM) programme, we develop clinical candidates with broad anti-inflammatory efficacy and the potential of significantly reduced side effects compared with available glucocorticoid-based therapies. The lead compound has successfully completed Phase I. We are currently planning for a clinical Phase II trial in 2024.